The US Patent and Trademark Office (USPTO) has provided VistaGen a notice of allowance regarding a patent covering the use of its PH10 nasal spray for the treatment of depression, the company said. VistaGen announced that it had licensed PH10, a neurosteroid nasal spray, from Pherin Pharmaceuticals in October 2018.
PH10 is currently in Phase 2 development for the treatment of major depressive disorder. According to VistaGen, a Phase 2a clinical study demonstrated that PH10 could produce significant reduction in symptoms “without systemic exposure, psychological side effects or safety concerns.”
The company said that it is planning a Phase 2b study of PH10 for major depressive disorder but did not specify when the study is expected to begin.
VistaGen CEO Shawn Singh commented, “With mechanisms of action that are fundamentally differentiated from current antidepressants, we believe both oral AV-101 and PH10 nasal spray have the potential to address the significant unmet medical need for new antidepressant agents with rapid-onset activity, convenient at-home administration, and an acceptable safety and tolerability profile.”
Read the VistaGen press release.
